News

Novan Satisfies $16.5 Million Outstanding Promissory Note

– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and…

2 years ago

Better Choice Completes Integration of TruDog Brand & Launches Halo® Branded Freeze-Dried Raw Meals, Treats and Toppers

NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE: BTTR) (the “Company” or “Better Choice”), a…

2 years ago

ICU Medical, Inc. Announces Time of Second Quarter 2022 Earnings Conference Call

SAN CLEMENTE, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and…

2 years ago

Milestone Scientific Names Hager & Werken as Exclusive STA Single Tooth Anesthesia System® Distributor in Germany and Austria

ROSELAND, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments,…

2 years ago

Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN),…

2 years ago

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access…

2 years ago

HTG Molecular Diagnostics Hosting a KOL Event Addressing Drug Candidate Attrition

TUCSON, Ariz., July 19, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing…

2 years ago

ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers

Oryzon and NCI will collaborate to assess the safety and efficacy of iadademstat in oncology patients with different hematological and…

2 years ago

Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities

FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare…

2 years ago